Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 2,715 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $29.62, for a total transaction of $80,418.30. Following the sale, the insider now owns 82,047 shares in the company, valued at approximately $2,430,232.14. This represents a 3.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Castle Biosciences Stock Up 1.7 %

NASDAQ CSTL opened at $32.72 on Thursday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The business’s fifty day simple moving average is $29.91 and its 200-day simple moving average is $27.78. The firm has a market cap of $916.39 million, a PE ratio of 163.61 and a beta of 0.92.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The company had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. During the same period in the previous year, the business posted ($0.26) EPS. As a group, equities analysts anticipate that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have commented on the company. Scotiabank raised their price objective on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a report on Wednesday, November 6th. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. KeyCorp increased their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. BTIG Research boosted their target price on shares of Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Lake Street Capital raised their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $40.29.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in shares of Castle Biosciences by 15.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 96,688 shares of the company’s stock valued at $2,105,000 after purchasing an additional 12,583 shares during the last quarter. Rhumbline Advisers boosted its stake in Castle Biosciences by 7.7% during the second quarter. Rhumbline Advisers now owns 41,896 shares of the company’s stock worth $912,000 after buying an additional 2,988 shares during the period. Acadian Asset Management LLC increased its position in shares of Castle Biosciences by 33.0% during the second quarter. Acadian Asset Management LLC now owns 280,497 shares of the company’s stock valued at $6,101,000 after acquiring an additional 69,673 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Castle Biosciences by 12.9% in the 2nd quarter. American Century Companies Inc. now owns 42,818 shares of the company’s stock valued at $932,000 after acquiring an additional 4,898 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Castle Biosciences by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock worth $17,631,000 after acquiring an additional 60,675 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.